ANXA5 and cancer: Moreover, earlier clinical development of radiolabeled annexin V (as Apomate®) was stalled because a one-to-one correspondence between 99mTc- 6-hydrazinopyridine-3-carboxylic acid-(HYNIC)-annexin V uptake and radiologic response to cancer chemotherapy was not found [19].